Theseus Pharmaceuticals, Inc. (THRX)

Theseus Pharmaceuticals, Inc. (THRX) — VMCI valuation read

THRX prints VMCI 39/100 inside the Healthcare sector, where the median sits at 50. The 11-point below-median delta is the cleanest single-number summary of Theseus Pharmaceuticals, Inc.'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.

On THRX, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** THRX trades at 22.0x earnings, 22% above the Healthcare median of 18.0x; that is the value line. ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of -0.7x leaves covenant headroom; that is the risk line for Theseus Pharmaceuticals, Inc. on the trailing financials.

THRX fell 1.7% over the trailing 7 days, with a -8.0% read on a 30-day basis.